Vamorolone

Buoyed by new data, Santhera preps filing for DMD drug vamorolone

A year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular dystrophy (DMD) therapy idebenone. Now, it’s ready to file replacement drug vamorolone, armed with new data from a pivotal trial, in what looks like a reversal of its fortunes. With prospects for idebenone looking shaky, Santhera snapped …

Buoyed by new data, Santhera preps filing for DMD drug vamorolone Read More »

Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy

Shots: The P-IIb VISION-DMD study involves assessing the efficacy & safety of vamorolone (2&6 mg/kg/day) vs PBO and prednisone (0.75 mg/kg/day) in 121 ambulant boys aged 4 to <7 years with DMD for 48 wks. The study met its 1EP i.e improvement in TTSTAND velocity, following the 1st period @24 wks. The 2 EPs include …

Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy Read More »